Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   94663 News 


«12...6263646566676869707172...10641065»
  • ||||||||||  fluticasone / Generic mfg.
    DAILY OR TWICE DAILY TREATMENT WITH TOPICAL STEROIDS RESULTS IN SIMILAR RESPONSE IN EOSINOPHILIC ESOPHAGITIS (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_908;    
    Patients on twice daily dosing were more frequently prescribed fluticasone (36% vs. 18%; p trend < 0...These results can help patients and providers decide how to best take a tCS and to be assured that either regimen is effective. Moreover given comparable efficacy a once daily total dose rather than divided dose could be considered to increase adherence while reducing the risk for candidal esophagitis.
  • ||||||||||  Noxafil (posaconazole) / Merck (MSD)
    Journal:  Cushing syndrome and tertiary adrenal insufficiency from prolonged concomitant use of budesonide and posaconazole. (Pubmed Central) -  Mar 14, 2024   
    However, concomitant use of posaconazole and voriconazole, inhibitors of CYP3A4 commonly used as antifungal prophylaxis in allograft patients receiving immunosuppression, can lead to substantial systemic steroid exposure. This paper describes a case of severe iatrogenic Cushing syndrome and tertiary adrenal insufficiency because of this interaction, highlighting the necessity for improved awareness of this phenomenon.
  • ||||||||||  REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche
    Review, Journal:  Plant-derived compounds as potential leads for new drug development targeting COVID-19. (Pubmed Central) -  Mar 14, 2024   
    Biological drugs including monoclonal antibodies, such as casirivimab and imdevimab, have also been authorised for emergency use in certain situations...This review explores the evaluation and potential therapeutic applications of these plants against SARS-CoV-2. This review summarises the latest evidence on the activity of different plant extracts and their isolated bioactive compounds against SARS-CoV-2, with a focus on the application of plant-derived compounds in animal models and in human studies.
  • ||||||||||  ketorolac / Generic mfg., dexamethasone / Generic mfg., isoflurane / Generic mfg.
    Journal:  Retrolaminar block for opioid-free anaesthesia and enhanced recovery after posterior lumbar discectomy: A randomised controlled study. (Pubmed Central) -  Mar 13, 2024   
    Primary outcomes were recovery time (time from isoflurane discontinuation to the first response to verbal command) and time to discharge (time from admission to the post-anaesthesia care unit (PACU) to discharge from the PACU, when Aldrete score was ?9)...The total consumption of ketorolac post-operatively was significantly reduced in the retrolaminar group compared to the control group (P < 0.001). Intra-operative retrolaminar block is an easy and effective opioid-free regional anaesthesia technique that improves recovery after posterior lumbar discectomy.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both? (Pubmed Central) -  Mar 13, 2024   
    Targeted-release budesonide is a therapeutic modality that aims to inhibit disease pathogenetic pathways at early stages; it has minor systemic absorption and proven beneficial effects on renal function and proteinuria. In the present systemic review, the benefits and adverse events of steroids and budesonide are described, and the possibility of combined treatment is questioned in selected cases with active histologic lesions.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial completion date, Trial primary completion date, Combination therapy:  Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) -  Mar 13, 2024   
    P2,  N=320, Recruiting, 
    In the present systemic review, the benefits and adverse events of steroids and budesonide are described, and the possibility of combined treatment is questioned in selected cases with active histologic lesions. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  abiraterone acetate / Generic mfg.
    Trial suspension:  Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 (clinicaltrials.gov) -  Mar 13, 2024   
    P1,  N=36, Suspended, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2024 Recruiting --> Suspended
  • ||||||||||  budesonide / Generic mfg., ipratropium bromide / Generic mfg.
    Retrospective data, Journal:  Probiotics combined with Budesonide and Ipratropium bromide for chronic obstructive pulmonary disease: A retrospective analysis. (Pubmed Central) -  Mar 12, 2024   
    After treatment, the levels of lactobacilli and bifidobacteria in the 2 groups increased compared to those before treatment, and the observation group had a higher level, while the levels of Enterobacteriaceae and Enterococcus were lower in the observation group than those before treatment (P?<?.05). Based on budesonide and irpratropium bromide, probiotic treatment of COPD is more conducive to reducing the degree of inflammatory reactions, inhibiting airway remodeling, regulating the level of gut microbiota, and promoting the recovery of lung function.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Trial completion date, Trial primary completion date:  Ixazomib + Pomalidomide + Dexamethasone In MM (clinicaltrials.gov) -  Mar 12, 2024   
    P1/2,  N=61, Recruiting, 
    Recruiting --> Suspended Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
  • ||||||||||  prednisolone / Generic mfg., methotrexate / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PREDMETH: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (clinicaltrials.gov) -  Mar 12, 2024   
    P4,  N=138, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Jun 2023 --> Jul 2024
  • ||||||||||  dazucorilant (CORT113176) / Corcept Therap
    Trial completion date, Trial primary completion date:  DAZALS: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) -  Mar 12, 2024   
    P2,  N=228, Recruiting, 
    No abstract available Trial completion date: Nov 2027 --> May 2027 | Trial primary completion date: May 2027 --> Oct 2024
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Exparel (bupivacaine liposome injectable suspension) / Pacira
    Trial completion date, Trial primary completion date, Surgery:  Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery (clinicaltrials.gov) -  Mar 12, 2024   
    P4,  N=192, Recruiting, 
    The quality of reporting on these patients when infected with COVID-19 is not uniform and further prospective or registry studies are needed to better guide clinical care in this unique setting. Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
  • ||||||||||  dexamethasone / Generic mfg.
    Single Port Retroperitoneal Adrenalectomy via Anterior Approach (Video Abstract Theater) -  Mar 12, 2024 - Abstract #AUA2024AUA_3472;    
    The SP robot performs well for adrenalectomy, especially via the retroperitoneal approach. We recommend its use for smaller, likely benign adrenal masses.
  • ||||||||||  dexamethasone / Generic mfg.
    Anti-inflammatory effect of Betulinic Acid Is Dependent on Metabolic Reprogramming of Immune Cells (303A) -  Mar 12, 2024 - Abstract #AUA2024AUA_2037;    
    P1/2
    High glucose averts the Jurkat cell proliferation evoked nutrient scarcity at the default state of normal glucose that triggers metabolic reprogramming and allow poisoning of mitochondria by BA. Since caloric restriction boosts immunity, the stunted antiproliferative effect of BA and SA implies that high glucose induces proliferation of immature immune cells and faster proliferation impedes maturation.
  • ||||||||||  triamcinolone acetonide topical / Generic mfg.
    Fractional CO2 laser for the treatment of Peyronie's Disease: a pilot study. (301B) -  Mar 12, 2024 - Abstract #AUA2024AUA_1944;    
    Fractional CO 2 laser therapy may serve as a safe and minimally invasive therapy for PD, with results at both 24 and 52 weeks being encouraging. Further clinical trials are warranted to evaluate the safety and efficacy of fractional CO 2 laser therapy in the treatment of PD.
  • ||||||||||  Journal:  HLH Syndrome in a Community Hospital: The Challenge of an Early Diagnosis. (Pubmed Central) -  Mar 12, 2024   
    Early intervention with corticosteroids and/or IVIG may prevent deterioration, spare them from chemotherapy and provide time for more elaborate testing to identify true HLH. Unfortunately, mortality remains a significant risk for these children.